Acute Myeloid Leukemia Pipeline Insight 2026: 100+ Companies Advancing Novel Therapies for Aggressive Myeloid Blood Cancer Management | DelveInsight

DelveInsight's "Acute Myeloid Leukemia Pipeline Insight, 2026" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Acute Myeloid Leukemia Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
• DelveInsight's Acute Myeloid Leukemia pipeline report depicts a robust space with approx. 100+ key active players working to develop 110+ pipeline therapies for Acute Myeloid Leukemia treatment.
• Orca Biosystems, Inc. leads the pipeline with its candidate, Orca-T, in the most advanced stage of development, Preregistration, among the Acute Myeloid Leukemia companies.
• The leading Acute Myeloid Leukemia companies include Orca Biosystems, Inc., Johnson & Johnson, Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., and others.
• Promising Acute Myeloid Leukemia therapies such as Orca-T, Bleximenib, Romaciclib, ABD-3001, CER-1236, PRO CAR-301, and others.

The Acute Myeloid Leukemia Pipeline report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain.

Acute Myeloid Leukemia Overview
Acute myeloid leukemia (AML) is a rapidly progressing myeloid neoplasm characterized by the clonal expansion of immature myeloid-derived cells, known as blasts, in the peripheral blood and bone marrow. This expansion results in ineffective erythropoiesis and megakaryopoiesis, clinically manifesting as relatively rapid bone marrow failure compared to chronic and indolent leukemias, leading to inadequate production of red blood cells and platelets.

Symptoms of AML typically develop over a few weeks, becoming more severe as immature white blood cell counts rise. These include pale or "washed out" skin, tiredness, breathlessness, unintended weight loss, frequent infections, easy bruising, flat red or purple skin spots, and bone or joint pain. Patients with myeloproliferative neoplasms such as myelofibrosis, essential thrombocythemia, polycythemia vera, and chronic myeloid leukemia can evolve into more aggressive myeloid malignancies like AML, characterized by declining blood counts and rising circulating blasts. Along with myelodysplastic syndromes and conditions such as aplastic anemia, these disorders are grouped under secondary acute myeloid leukemia.

AML should be suspected in patients with rapidly developing unexplained cytopenias, circulating blast cells in peripheral blood, easy bruising or bleeding, or recurrent infections. Laboratory findings reflecting high tumor burden and rapid cell turnover may include elevated LDH, uric acid, potassium, and phosphorus levels. Once diagnosis is confirmed, baseline assessments such as ECG and 2D echocardiography are recommended to evaluate cardiac function and anticipate cardiotoxic treatment effects. Management is based on risk-adapted, multi-modal therapy integrating intensive cytotoxic chemotherapy, molecularly targeted approaches, and hematopoietic stem cell transplantation. Induction therapy aims to achieve complete remission through eradication of leukemic blasts using combination regimens that disrupt DNA synthesis and induce apoptosis, followed by consolidation therapy to eliminate minimal residual disease and reduce relapse risk, guided by cytogenetic and molecular risk stratification.

From emerging drug candidates to competitive intelligence, the Acute Myeloid Leukemia Pipeline Report covers it all @ https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Acute Myeloid Leukemia Emerging Drugs
• Orca-T: Orca Biosystems, Inc.
Orca-T is an investigational allogeneic T-cell immunotherapy under evaluation for the treatment of multiple hematologic malignancies including acute leukemias and myelodysplastic syndromes. It is composed of highly purified regulatory T-cells, hematopoietic stem cells, and conventional T-cells derived from either related or unrelated matched donors. Currently, the drug is being evaluated in the Preregistration stage of development for the treatment of Acute Myeloid Leukemia.

• Bleximenib: Johnson & Johnson
Bleximenib (JNJ-75276617) is an investigational, oral, small-molecule menin-KMT2A inhibitor showing promising activity against AML with KMT2A rearrangements or NPM1 mutations. It targets a key oncogenic interaction between menin and KMT2A fusion proteins, disrupting a pathway that drives leukemic cell growth in patients with KMT2Ar or NPM1m mutations. Currently, the drug is being evaluated in the Phase III stage of development for the treatment of Acute Myeloid Leukemia.

• Romaciclib: Ryvu Therapeutics
Romaciclib is a highly selective inhibitor of CDK8 and CDK19, minimizing off-target effects and enhancing therapeutic efficacy. This targeted approach disrupts key transcriptional programs essential for cancer cell survival while sparing healthy cells, and has demonstrated a low potential for drug-drug interactions, supporting better overall treatment outcomes. Currently, the drug is being evaluated in the Phase II stage of development for the treatment of Acute Myeloid Leukemia.

• ABD-3001: Advanced BioDesign
ABD-3001 is a small-molecule inhibitor of the ALDH family of enzymes at the initial stage of clinical development for a wide range of cancers, including acute myeloid leukemia. The drug irreversibly binds to and inhibits ALDH1 and ALDH3, leading to metabolic stress and destruction of cancer stem cells. Currently, the drug is being evaluated in the Phase I/II stage of development for the treatment of Acute Myeloid Leukemia.

• CER-1236: CERo Therapeutics Holdings, Inc.
CER-1236 is an autologous chimeric engulfment receptor T cell (CER-T) that fuses the external domain of TIM-4 with intracellular domains from T cells and innate immune cells including Toll-like receptor 2 (TLR2), CD28, and CD3ζ. This receptor binds TIM-4-ligand (phosphatidylserine) on tumor cells, leading to phagocytosis and lysis of target cells followed by tumor antigen processing and cross-presentation to induce an adaptive immune response. CER-1236 was shown to eliminate AML cells in vitro and in vivo in a xenograft model. Currently, the drug is being evaluated in the Phase I stage of development for the treatment of Acute Myeloid Leukemia.

• PRO CAR-301: Promicell INC.
PRO CAR-301 is an autologous CD33-directed CAR T cell that integrates a next-generation armor known as "SAVVY/IL-18," making it an armored CD33-specific CAR T therapy for acute myeloid leukemia. It targets CD33, a cell surface protein expressed by mature myeloid cells and hematopoietic stem cells that is present on over 80% of AML cells, making it an effective treatment target. Currently, the drug is being evaluated in the preclinical stage of development for the treatment of Acute Myeloid Leukemia.

Want to know which companies are leading innovation in Acute Myeloid Leukemia? Dive into the full pipeline insights @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Acute Myeloid Leukemia Companies
Orca Biosystems, Inc., Johnson & Johnson, Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., and others.

Acute Myeloid Leukemia Clinical Trial Phases
DelveInsight's report covers around 110+ products under different phases of clinical development like:
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Acute Myeloid Leukemia Drug Route of Administration
Acute Myeloid Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acute Myeloid Leukemia Product Molecule Type
Acute Myeloid Leukemia products have been categorized under various molecule types such as:
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Acute Myeloid Leukemia Pipeline Report
• Coverage- Global
• Acute Myeloid Leukemia Companies- Orca Biosystems, Inc., Johnson & Johnson, Ryvu Therapeutics, Advanced BioDesign, CERo Therapeutics Holdings, Inc., Promicell INC., and others.
• Acute Myeloid Leukemia Therapies- Orca-T, Bleximenib, Romaciclib, ABD-3001, CER-1236, PRO CAR-301, and others.
• Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Acute Myeloid Leukemia Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Content
1. Introduction
2. Executive Summary
3. Acute Myeloid Leukemia (AML): Overview
4. Pipeline Therapeutics
5. Comparative Analysis
6. Therapeutic Assessment
7. Acute Myeloid Leukemia (AML) - DelveInsight's Analytical Perspective
8. Late Stage Products (Preregistration)
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Preclinical and Discovery Stage Products
12. Inactive Products
13. Acute Myeloid Leukemia (AML) Key Companies
14. Acute Myeloid Leukemia (AML) Key Products
15. Acute Myeloid Leukemia (AML) - Unmet Needs
16. Acute Myeloid Leukemia (AML) - Market Drivers and Barriers
17. Acute Myeloid Leukemia (AML) - Future Perspectives and Conclusion
18. Acute Myeloid Leukemia (AML) Analyst Views
19. Appendix

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.